Pembrolizumab significantly improved progression-free survival vs brentuximab in a recent phase 3 trial with patients with relapsed or refractory classical Hodgkin lymphoma. Medscape Medical News
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
Pembrolizumab Prolonged PFS vs Brentuximab in Hodgkin Lymphoma
Medscape: Hematology/Oncology Headlines | Geplaatst op 01.06.2020 18:40